目的 了解肿瘤异常糖链蛋白(TAP)在基于氟尿嘧啶类药物化疗的胃肠道恶性肿瘤患者外周血中的表达情况,探讨影响其表达的因素及临床意义。方法 本研究纳入2018年5月至12月病理诊断确诊为胃癌及结直肠癌患者99例,其中氟尿嘧啶联合紫杉醇治疗后的胃癌患者53例,氟尿嘧啶联合奥沙利铂治疗后的结直肠癌患者46例,检测其TAP值,收集患者的基本资料、癌种、分期及血清肿瘤标记物等情况,分析TAP在不同特征消化道肿瘤中的表达差异。结果 TAP在基于氟尿嘧啶类药物化疗的胃肠道恶性肿瘤患者外周血中的表达值为(158.11±33.63),TAP值的表达在不同性别、年龄、癌种、临床分期及血清肿瘤标记物表达情况之间无统计学差异。结论 TAP在基于氟尿嘧啶类药物化疗的胃肠道恶性肿瘤患者中表达无差异,还不能作为鉴别诊断不同特征的消化道恶性肿瘤的依据。
Abstract
OBJECTIVE To acquire the expressing information about tumor abnormal glycoprotein (TAP) in the peripheral blood of the gastric cancer patients who are treated with fluorouracil and the colorectal cancer patients treated with fluorouracil, and to discuss the factors that affect its expression and its clinical significance. METHODS This research was conducted on the basis of 99 gastric cancer patients and colorectal cancer patients whose diseases were pathologically diagnosed from May to December, 2018, including 53 gastric cancer patients treated with fluorouracil and paclitaxel and 46 colorectal cancer patients treated with fluorouracil and oxaliplatin. It tested their TAP values, collected the basic information, the type of the cancer, the stage of the cancer, serum tumor markers, etc. of the patients as well as analyzed the differences of the expression of TAP in gastrointestinal tumors with different characteristics. RESULTS The expression value of TAP in the peripheral blood of the gastrointestinal cancer patients is (158.11±33.63), and the expression of TAP value has no statistical differences in the expression of different sexes, ages, types of the cancer, clinical stages and serum tumor markers. CONCLUSION The fact that the expression of TAP has no differences in the gastrointestinal cancer patients with different characteristics can′t be taken as the basis of identifying or diagnosing gastrointestinal tumors which are different in character.
关键词
肿瘤异常糖链蛋白 /
氟尿嘧啶 /
胃癌 /
结直肠癌 /
表达差异
{{custom_keyword}} /
Key words
tumor abnormal glycoprotein (TAP) /
fluorouracil /
gastric cancer /
colorectal cancer /
expression difference
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] DUAN J J, YAN Y Q, YANG N N, et al. International comparison analysis of China′s cancer incidence and mortality[J]. Chin J Frontiers Med Sci(中国医学前沿杂志电子版), 2016, 8(7):17-23.
[2] CHEN W Q, ZENG R S, ZENG H M, et al. Report of cancer incidence and mortality in China, 2011[J]. China Cancer(中国肿瘤), 2015, 24(1):1-10.
[3] LI M, SONG L, QIN X. Glycan changes: cancer metastasis and anti-cancer vaccines[J]. J Biosci, 2010, 35 (4):665-673.
[4] BING Z, LU Y, SUN L R, et al. The role of abnormal sugar chain glycoprotein in the accurrence and development of tumorigenesis and the progress of detection [J]. Qilu Med J(齐鲁医学杂志), 2015, 30(2):245-246,252.
[5] DUBE D H, BERTOZZI C R. Glycans in cancer and inflammation--potential for therapeutics and diagnostics[J]. Nat Rev Drug Discov, 2005, 1(6):477-488.
[6] ZHANG Q F, LI Y Z, LI J X. The value of serum CA199, CA242 and CA724 in the diagnosis of malignant tumor of digestive system [J]. J Shanxi Med Univ(山西医科大学学报), 2007(5):430-432.
[7] JIN H, ZHAN H G, CUI X. Evaluationof the efficacy of tumor abnormal protein detection system in the detection of digestive systemtumors[J]. Mod Med(现代医学), 2006(4):270-271.
[8] QIU Z Y, TAO S, LEI Z, et al. The clinical value of tumor abnormal protein in gastrointestinal tumor [J]. Cancer Prog(癌症进展), 2016, 14(4):340-342.
[9] ZHAO L N, ZHANG L. The value of tumorabnormal protein in the diagnosis of head and neck tumors [J]. Zhejiang Integr Tradit Western Med(浙江中西医结合杂志), 2015, 25(9):846-847.
[10] XU R T, XU Y L, WANG T, et al. The expression of abnormal protein in peripheral blood of patients with lung cancer and its clinical significance[J]. Cancer Prog(癌症进展), 2018, 16(13):1644-1646.
[11] YIN Y, YAO X B, ZHAO Y R. The value of abnormal tumor protein in the diagnosis and prognosis evaluation of hepatocellular carcinoma[J]. Shanxi Med J(陕西医学杂志), 2016, 45(9):1253-1255.
[12] YUE X G, XU X Y. The expression of tumor abnormal protein in the malignanttumor of the digestive tract and the evaluation of the curative effect [J]. J Clin Med, Elec J(临床医药文献电子杂志), 2017, 4(8):1431-1432.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1323 KB)
